Company Focus
argenx
Latest argenx News
Biotechnology
The US Food and Drug Administration (FDA) late Friday approved a label expansion for Netherlands-based argenx’ Vyvgart efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG). 9 May 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and broader neurodegenerative biology. Neurizon aims to advance its lead small-molecule candidate into pivotal clinical testing and position it for regulatory evaluation and eventual patient access.
Latest News & Features of interest to argenx
Pharmaceutical
Among licensing news of note last week, US drug developer Agios Pharma struck a deal with South Korea’s Oscotec for the latter’s cevidoplenib, a potential treatment for immune thrombocytopenia. US major AbbVie won European Commission approval for its migraine drug Aquipta. Travere Therapeutics licensed rights to civorebrutinib from China’s Everest Medicines, and Alnylam Pharmaceuticals entered into an AI collaboration with Inceptive Nucleics worth a potential $2 billion. 7 June 2026
Pharmaceutical
Chiesi Global Rare Diseases, a unit of privately-held Italian drugmaker Chiesi, announced that the European Commission (EC) has approved Lojuxta (lomitapide) capsules for use in children 5 years of age and older with homozygous familial hypercholesterolemia (HoFH), for use alongside diet and other lipid-lowering treatments, including LDL-apheresis where available. 6 June 2026
Generics
Russia will have its own generic of one of the world’s most expensive drug against cystic fibrosis, as the Russian pharmaceutical company Amedart announced its plans launch a domestic analogue of Trikafta (elexacaftor/tezacaftor/ivacaftor), a drug from the American company Vertex Pharmaceuticals for the treatment of cystic fibrosis, reports The Pharma Letter’s local correspondent. 5 June 2026
Biotechnology
Japan’s Otsuka announced that Voyxact (sibeprenlimab-szsi) preserved kidney function compared to placebo over 12 months in adults with primary IgA nephropathy (IgAN) at risk for disease progression. 5 June 2026
Biotechnology
US biotech Biogen has received US Food and Drug Administration (FDA) Breakthrough Therapy designation for salanersen, its investigational antisense oligonucleotide for spinal muscular atrophy (SMA). 5 June 2026
Pharmaceutical
The 2026 American Society of Clinical Oncology (ASCO) annual meeting delivered several potentially practice-changing datasets across solid tumors and hematologic malignancies, while underlining the growing influence of Chinese biotech innovation, antibody-drug conjugates and next-generation targeted therapies. 4 June 2026
Biotechnology
US drugmaker Gilead Sciences today announced that the UK’s National Institute for Health and Care Excellence (NICE) has approved Livdelzi (seladelpar) for the use on the National Health Service (NHS) in England within its marketing authorization as an option for treating primary biliary cholangitis (PBC). 4 June 2026
Pharmaceutical
A feature on the amyloidosis space. 4 June 2026
Biotechnology
Shares in Switzerland-based ADC Therapeutics fell sharply in pre-market trading on Thursday after investors focused on safety findings and the lack of a clear overall survival advantage in the Phase III LOTIS-5 trial of Zynlonta (loncastuximab tesirine-lpyl) plus rituximab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). 4 June 2026
Biotechnology
Australian clinical-stage biotech Neurizon Therapeutics is expanding the NUZ-001 arm of the HEALEY ALS Platform Trial after recruitment ran faster than expected. 4 June 2026
Latest In Brief for argenx
Pharmaceutical
A consortium led by CVC Capital Partners has launched a 10.9 billion euros ($12.65 billion) bid to take Italian drugmaker Recordati (RECI: MI) private, in a deal that would tighten the buyout specialist’s control of the company and extend its bet on the rare disease market. 23 May 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze